BridgeBio Oncology Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from BridgeBio Oncology Therapeutics, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.8 times its market value (net cash). Higher than 95% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 93% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-218.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 93% of Healthcare companies in United States.
Cash Cushion Ratio
1.8× cashCash, after subtracting all debt, is 1.8 times its market value (net cash).
Higher than 95% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
BridgeBio Oncology Therapeutics, Inc. made a loss over the last year. BridgeBio Oncology Therapeutics, Inc. owes $0.14 for every $1 it owns. BridgeBio Oncology Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBridgeBio Oncology Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.71The share price is 0.71 times BridgeBio Oncology Therapeutics, Inc.'s book value per share, lower than 86% of Healthcare companies in United States.
Market cap
$228 MThe total market value of all of BridgeBio Oncology Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 56% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$323 MWhat BridgeBio Oncology Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.03Net worth divided by the number of shares. The share price of $2.85 is 0.7 times this, which is the P/B above.
Return on equity (ROE)
-81.9%BridgeBio Oncology Therapeutics, Inc. lost 81.9% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
Owes vs Owns
0.14×BridgeBio Oncology Therapeutics, Inc. owes $0.14 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Dividend yield
NoneBridgeBio Oncology Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossBridgeBio Oncology Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashBridgeBio Oncology Therapeutics, Inc. held $423 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For BridgeBio Oncology Therapeutics, Inc.: $228 M ÷ $323 M (30 Jun 2026) = 0.7.
What is BridgeBio Oncology Therapeutics, Inc.'s return on equity?
BridgeBio Oncology Therapeutics, Inc. lost 81.9% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
How much does BridgeBio Oncology Therapeutics, Inc. owe compared with what it owns?
BridgeBio Oncology Therapeutics, Inc. owes $0.14 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Does BridgeBio Oncology Therapeutics, Inc. pay a dividend?
No. BridgeBio Oncology Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.